Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 46,529 | 53,572 | 56,953 | 90,466 | 144,761 |
| Receivables | 22,592 | 19,572 | 17,781 | 40,284 | 23,094 |
| Inventories | 18,442 | 20,905 | 20,604 | 21,568 | 40,039 |
| TOTAL | $109,602 | $118,447 | $120,719 | $185,182 | $237,512 |
| Non-Current Assets | |||||
| PPE Net | 4,023 | 4,419 | 4,816 | 5,214 | 5,622 |
| Intangibles | 104,097 | 113,107 | 118,127 | 131,128 | 136,148 |
| Other Non-Current Assets | 17,276 | 17,739 | 33,196 | 34,530 | 56,612 |
| TOTAL | $125,396 | $135,265 | $156,139 | $170,872 | $198,382 |
| Total Assets | $234,998 | $253,712 | $276,858 | $356,054 | $435,894 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 8,000 | 24,000 | 24,000 | 32,000 | 65,947 |
| Accounts payable and accrued liabilities | 9,038 | 11,776 | 12,577 | 18,021 | 19,708 |
| Accrued Expenses | 62,664 | 56,408 | 46,367 | 75,777 | 87,364 |
| Other current liabilities | N/A | N/A | N/A | N/A | 13,681 |
| TOTAL | $79,702 | $92,184 | $82,944 | $129,536 | $187,965 |
| Non-Current Liabilities | |||||
| Long Term Debt | 34,613 | 18,486 | 26,296 | 34,078 | N/A |
| Deferred Revenues | 0 | 0 | 0 | 3,738 | 1,265 |
| Other Non-Current Liabilities | 116,809 | 126,553 | 138,674 | 143,914 | 190,780 |
| TOTAL | $194,718 | $188,335 | $208,266 | $221,288 | $234,076 |
| Total Liabilities | $274,420 | $280,519 | $291,210 | $350,824 | $422,041 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 188,389 | 188,314 | 185,928 | 184,248 | 183,962 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,609,564 | -1,595,075 | -1,579,130 | -1,557,025 | -1,545,361 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $-39,422 | $-26,807 | $-14,352 | $5,230 | $13,853 |
| Total Liabilities And Equity | $234,998 | $253,712 | $276,858 | $356,054 | $435,894 |